SCHEMBL3083707

SCHEMBL3083707

COc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OC(C)c5ccccn5)cnc43)cc2)cn1

nearest known ligand 0.67

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ALOX5AP P20292 20/20 0.67
PTGS1 P23219 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20475102 0.92 ALOX5AP (0.79) ALOX5APPTGS1
SCHEMBL167773 0.92 ALOX5AP (0.79) ALOX5APPTGS1
SCHEMBL170021 0.92 ALOX5AP (0.79) ALOX5APPTGS1
SCHEMBL3105482 0.90 ALOX5AP (0.59) ALOX5APPTGS1
SCHEMBL3105537 0.89 ALOX5AP (0.69) ALOX5AP
SCHEMBL3096211 0.89 ALOX5AP (0.69) ALOX5AP
SCHEMBL3088762 0.88 ALOX5AP (0.83) ALOX5APPTGS1
SCHEMBL3105490 0.86 ALOX5AP (0.58) ALOX5APPTGS1
SCHEMBL3099749 0.86 ALOX5AP (0.59) ALOX5APPTGS1
SCHEMBL20475071 0.86 ALOX5AP (0.70) ALOX5APPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1933842-B1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS PANMIRA PHARMACEUTICALS LLC (US) 2012-10-03 EP disclosed
US-7795274-B2 5-lipoxygenase-activating protein (FLAP) inhibitors AMIRA PHARMACEUTICALS INC. (US) 2010-09-14 US disclosed
US-20080227807-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2008-09-18 US disclosed
US-7405302-B2 5-lipoxygenase-activating protein (FLAP) inhibitors AMIRA PHARMACEUTICALS, INC. (US) 2008-07-29 US disclosed
US-20070123522-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227807-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS ALOX5, ALOX15B, ALOX15 ALOX5AP 4/4885PTGS1 27/4885
US-20070123522-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS ALOX5, ALOX15B, ALOX15 ALOX5AP 4/4885PTGS1 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.